Baxter International | BAX - Los Gastos De Explotación





Los Gastos De Explotación Cambio Fecha
Abbott USD 11.66B 1.2B 2026-09
AngioDynamics USD 81.95M 1.68M 2025-09
Artivion USD 111.2M 9.45M 2025-12
AtriCure USD 143.94M 3.22M 2026-06
Baxter International USD 6.5B 3.82B 2026-09
Becton, Dickinson and Co. USD 24.42B 283M 2026-06
Boston Scientific USD 4.13B 72M 2026-09
Cooper Companies USD 844.2M 268.3M 2026-06
Dexcom USD 990.1M 53.5M 2026-06
Edwards Lifesciences USD 1.22B 87.6M 2026-06
Fresenius EUR 5.23B 9M 2026-06
Globus Medical USD 835.58M 239.73M 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
ICU Medical USD 491.25M 8.59M 2026-06
Inogen USD 49.14M 665K 2024-09
Insulet USD 672M 32.3M 2026-06
Integra LifeSciences USD 368.53M 674.84M 2026-09
Intuitive Surgical USD 2B 86.5M 2026-09
J&J USD 18.93B 1.09B 2026-09
Laboratory Of America USD 3.39B 117.6M 2026-09
Medtronic USD 7.92B 203M 2026-06
Merit Medical Systems USD 358.44M 20.72M 2026-06
Quest Diagnostics USD 2.62B 34M 2026-09
Smith & Nephew USD 2.59B 71M 2026-06
Stryker USD 4.8B 118M 2026-06
Tandem Diabetes Care USD 268.35M 3.7M 2026-06
Teleflex USD 2.9B 179.9M 2026-06
Terumo JPY 222.33B 46.54B 2026-06
Zimmer Biomet Holdings USD 1.83B 140.7M 2026-06